Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 27fludarabine 18Rituximab 17obinutuzumab 11venetoclax 9Bendamustine Hydrochloride 9Lenalidomide 8zanubrutinib 6Prednisone 6Doxorubicin 6Blood Specimen Collection 6pembrolizumab 5fludarabine phosphate 5Biopsy 5ibrutinib 4glofitamab 4Vincristine 4Trimethoprim, Sulfamethoxazole Drug Combination 4Exercise 4loncastuximab tesirine 3gamma-Globulins 3axicabtagene ciloleucel 3acalabrutinib 3Temozolomide 3Surveys and Questionnaires 3Palliative Care 3Mycophenolic Acid 3Methotrexate 3Mesna 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma × Biological Assay × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡